Transcode Therapeutics, Inc.
TransCode Therapeutics is an emerging RNA oncology company, created on the belief that cancer can be defeated through the intelligent design and effective delivery of RNA therapeutics. We have created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which causes approximately 90% of all cancer deaths representing over nine million deaths per year worldwide. We believe that TTX-MC138 has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others. Our drug candidates, TTX-siPDL1 and TTX-siLIN28b, focus on the treatment of tumors by targeting PD-L1 and Lin28b, respectively.
(Note: TransCode Therapeutics priced its IPO on July 8, 2021, in line with the terms in its amended prospectus: 6.25 million shares at $4 to raise $25 million. On May 3, 2021, TransCode Therapeutics cut its IPO price to $4, down from a range of $8 to $10, and raised the number of shares to 6.3 million, up from 2.8 million, according to an S-1/A filing. The estimated IPO proceeds are the same – $25.2 million – but the market valuation, based on mid-point pricing, was cut by 37 percent to about $48 million on the current terms, down from $76.41 million previously.)
|Address||6 Liberty Square, #2382 Boston, MA 02109|
|Phone Number||(857) 837-3099|
|View Prospectus:||Transcode Therapeutics, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-2.34 mil (last 12 months)|
|Price range||$4.00 - $4.00|
|Est. $ Volume||$25.0 mil|
|Manager / Joint Managers||ThinkEquity (a division of Fordham Financial Management)|
|Expected To Trade:||7/9/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|